Moxonidine, a Mixed α2-Adrenergic and Imidazoline Receptor Agonist, Identifies a Novel Adrenergic Target for Spinal Analgesia

Laura S. Stone; Carolyn A. Fairbanks; George L. Wilcox

doi:10.1196/annals.1304.051

Moxonidine, a Mixed α₂-Adrenergic and Imidazoline Receptor Agonist, Identifies a Novel Adrenergic Target for Spinal Analgesia

Laura S. Stone, Carolyn A. Fairbanks, George L. Wilcox

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Moxonidine is a mixed α₂-adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of α₂-adrenoceptor (α ₂AR) agonists, does not require activation of the α _2AAR subtype, which mediates many of the side effects associated with α₂AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.

Original language	English (US)
Pages (from-to)	378-385
Number of pages	8
Journal	Annals of the New York Academy of Sciences
Volume	1009
DOIs	https://doi.org/10.1196/annals.1304.051
State	Published - 2003

Keywords

Intrathecal
Pain
Synergy
α adrenergic receptor

Access

10.1196/annals.1304.051

OpenUrl availability

Full text

Cite this

@article{e525a85836534934986b256a60b3ae71,

title = "Moxonidine, a Mixed α2-Adrenergic and Imidazoline Receptor Agonist, Identifies a Novel Adrenergic Target for Spinal Analgesia",

abstract = "Moxonidine is a mixed α2-adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of α2-adrenoceptor (α 2AR) agonists, does not require activation of the α 2AAR subtype, which mediates many of the side effects associated with α2AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.",

keywords = "Intrathecal, Pain, Synergy, α adrenergic receptor",

author = "Stone, {Laura S.} and Fairbanks, {Carolyn A.} and Wilcox, {George L.}",

year = "2003",

doi = "10.1196/annals.1304.051",

language = "English (US)",

volume = "1009",

pages = "378--385",

journal = "Annals of the New York Academy of Sciences",

issn = "0077-8923",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Moxonidine, a Mixed α2-Adrenergic and Imidazoline Receptor Agonist, Identifies a Novel Adrenergic Target for Spinal Analgesia

AU - Stone, Laura S.

AU - Fairbanks, Carolyn A.

AU - Wilcox, George L.

PY - 2003

Y1 - 2003

N2 - Moxonidine is a mixed α2-adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of α2-adrenoceptor (α 2AR) agonists, does not require activation of the α 2AAR subtype, which mediates many of the side effects associated with α2AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.

AB - Moxonidine is a mixed α2-adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of α2-adrenoceptor (α 2AR) agonists, does not require activation of the α 2AAR subtype, which mediates many of the side effects associated with α2AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.

KW - Intrathecal

KW - Pain

KW - Synergy

KW - α adrenergic receptor

UR - http://www.scopus.com/inward/record.url?scp=1342305375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342305375&partnerID=8YFLogxK

U2 - 10.1196/annals.1304.051

DO - 10.1196/annals.1304.051

M3 - Article

C2 - 15028616

AN - SCOPUS:1342305375

SN - 0077-8923

VL - 1009

SP - 378

EP - 385

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

ER -